跳至主要内容
临床试验/NCT03366376
NCT03366376Unknown2 期

A Phase II Multi-institutional Study of Hippocampus-sparing Whole Brain Radiotherapy and Simultaneous Integrated Boost for Multiple Brain Metastases From Non-small Cell Lung Cancer

Samsung Medical Center2 个研究点 分布在 2 个国家目标入组 80 人开始时间: 2017年12月11日最近更新:
适应症

试验速览

阶段
2 期
入组人数
80
试验地点
2
主要终点
Intracranial progression free survival

研究概览

简要总结

This study evaluates hippocampus-sparing whole-brain radiotherapy with simultaneous integrated boost for patients with multiple brain metastases from non-small cell lung cancer. The primary endpoint is intracranial progression free survival, and secondary endpoints are verbal neurocognitive function, overall survival, adverse events according to CTCAE v4.03, and quality of life.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
55 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Pathologically proven diagnosis of primary non-small cell lung cancer
  • 3 or more measurable brain metastasis ≥3 mm outside a 5-mm margin around either hippocampus on gadolinium contrast enhanced MRI within 14 days prior to registration
  • Age ≥55 years
  • Informed consent prior to study entry

排除标准

  • Patients with leptomeningeal metastases
  • ≥3 organ sites of extracranial metastases (including lung-to-lung metastases) within 3 months
  • Contraindication to MRI such as implanted metal devices or foreign bodies
  • Prior radiation therapy (including SRS) to the brain

结局指标

主要结局

Intracranial progression free survival

时间窗: until 12 months

Time from the date of start of radiotherapy to the date of death or intracranial progression

次要结局

  • Quality of life(3,6,12 months)
  • Adverse events(3,6,12 months)
  • Verbal neurocognitive function (Seoul Verbal Learning Test-Elderly, SVLT-E)(3,6,12 months)
  • Overall survival(until 12 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验